DelveInsight’s, “Epilepsy Pipeline Insight, 2023” report provides comprehensive insights about 75+ companies and 90+ pipeline drugs in Epilepsy pipeline landscape. It covers the Epilepsy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Epilepsy Pipeline Report
- DelveInsight’s Epilepsy pipeline report depicts a robust space with 75+ active players working to develop 90+ pipeline therapies for Epilepsy treatment.
- The leading companies working in the Epilepsy market include UCB, SK Life Science, Stoke Therapeutics, Xenon Pharmaceuticals, Epygenix, Bright Minds Biosciences, Neurona Therapeutics, Cevevel Therapeutics, PTC Therapeutics, Addex Pharmaceuticals, Equilibre Biopharmaceuticals B.V., ES Therapeutics Australia Pty Ltd, Overseas Pharmaceuticals, Anavex Life Sciences, Eliem Therapeutics, Ovid Therapeutics, CAMP4 Therapeutics, LifeSplice, Virpax Pharmaceuticals, Neuroene Therapeutics, and others.
- Promising Epilepsy Pipeline Therapies in the various stages of development include topiramate, Lacosamide, Levetiracetam, UCB0942, Intravenous Carbamazepine (IV CBZ), Diazepam Buccal Film, XEN1101, and others.
- On January 2023, Xenon Pharmaceuticals Inc. announced a study of Phase 2 Clinical Trials for XEN1101. The XEN1101 Phase 2 clinical trial is a randomized, double-blind, placebo-controlled study that will evaluate the clinical efficacy, safety and tolerability of increasing doses of XEN1101 administered as adjunctive treatment in adult patients diagnosed with focal epilepsy, followed by an optional open-label extension (OLE).
- On May 2023, Eisai Inc. announced a study of Phase 2 Clinical Trials for Perampanel. The purpose of this study is to evaluate the pharmacokinetics (PK) of perampanel during the Maintenance Period of the Core Study following oral suspension administration given as an adjunctive therapy in pediatric participants from 1 month to less than 4 years of age with epilepsy.
- On May 2023, Equilibre Biopharmaceuticals B.V. announced a study of Phase 2 Clinical Trials for EQU-001. This is a double-blind, placebo controlled, randomized study of dose-ranging safety, tolerability, exploratory efficacy of adjunctive EQU-001 for seizures using the continuous reassessment method in patients diagnosed with epilepsy.
Request a sample and discover the recent advances in Epilepsy Treatment Drugs @ Epilepsy Pipeline Report
The Epilepsy pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Epilepsy drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Epilepsy clinical trial landscape.
Epilepsy Overview
Epilepsy is one of the most common serious brain conditions, affecting over 50 million people worldwide. Epilepsy is a neurological disorder that is characterized by an enduring predisposition to generate epileptic seizures and the associated cognitive, psychological, and social consequences.
Find out more about Epilepsy Treatment Drugs @ Drugs for Epilepsy Treatment
Epilepsy Emerging Drugs Profile
- ZX008 (Fenfluramine Hydrochloride): UCB
- Cenobamate: SK Life Science, Inc.
- STK-001: Stoke Therapeutics
- EPX-100: Epygenix
- NRTX-1001: Neurona Therapeutics
- BMB-101: Bright Minds Biosciences
Epilepsy Pipeline Therapeutics Assessment
The Epilepsy pipeline report proffers an integral view of the Epilepsy emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.
Learn more about the emerging Epilepsy Pipeline Therapies @ Epilepsy Clinical Trials Assessment
Scope of the Epilepsy Pipeline Report
- Coverage- Global
- Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Epilepsy Companies- UCB, SK Life Science, Stoke Therapeutics, Xenon Pharmaceuticals, Epygenix, Bright Minds Biosciences, Neurona Therapeutics, Cevevel Therapeutics, PTC Therapeutics, Addex Pharmaceuticals, Equilibre Biopharmaceuticals B.V., ES Therapeutics Australia Pty Ltd, Overseas Pharmaceuticals, Anavex Life Sciences, Eliem Therapeutics, Ovid Therapeutics, CAMP4 Therapeutics, LifeSplice, Virpax Pharmaceuticals, Neuroene Therapeutics, and others.
- Epilepsy Pipeline Therapies- topiramate, Lacosamide, Levetiracetam, UCB0942, Intravenous Carbamazepine (IV CBZ), Diazepam Buccal Film, XEN1101, and others.
Dive deep into rich insights for new drugs for Epilepsy Treatment, Visit @ Epilepsy Market Drivers and Barriers, and Future Perspective
Table of Content
- Introduction
- Executive Summary
- Epilepsy: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Epilepsy– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- ZX008 (Fenfluramine Hydrochloride): UCB
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- STK-001: Stoke Therapeutics
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- BMB-101: Bright Minds Biosciences
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- NT102: Neuroene Therapeutics
- Drug profiles in the detailed report…..
- Inactive Products
- Epilepsy Key Companies
- Epilepsy Key Products
- Epilepsy- Unmet Needs
- Epilepsy- Market Drivers and Barriers
- Epilepsy- Future Perspectives and Conclusion
- Epilepsy Analyst Views
- Epilepsy Key Companies
- Appendix
For further information on the Epilepsy Pipeline therapeutics, reach out to Epilepsy Unmet Needs and Analyst Views
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting